Literature DB >> 28471501

Letter to Editor in Response to Johnson's Commentary (2017) on the Witkiewitz and Colleagues (2017) Article.

Raye Z Litten1, Daniel E Falk1, Stephanie S O'Malley2, Katie A Witkiewitz3, Karl F Mann4, Raymond F Anton5.   

Abstract

Entities:  

Year:  2017        PMID： 28471501      PMCID： PMC5513171          DOI： 10.1111/acer.13411

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN： 0145-6008            Impact factor:   3.455


× No keyword cloud information.
  8 in total

1.  Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials.

Authors:  Daniel Falk; Xin Qun Wang; Lei Liu; Joanne Fertig; Margaret Mattson; Megan Ryan; Bankole Johnson; Robert Stout; Raye Z Litten
Journal:  Alcohol Clin Exp Res       Date:  2010-12       Impact factor: 3.455

Review 2.  Pharmacotherapies for alcohol problems: a review of research with focus on developments since 1991.

Authors:  R Z Litten; J Allen; J Fertig
Journal:  Alcohol Clin Exp Res       Date:  1996-08       Impact factor: 3.455

Review 3.  Pharmacotherapy of alcohol use disorders: seventy-five years of progress.

Authors:  Leah R Zindel; Henry R Kranzler
Journal:  J Stud Alcohol Drugs Suppl       Date:  2014

4.  Toward Rational, Evidence-Based, and Clinically Relevant Measures to Determine Improvement Following Treatment for Alcohol Use Disorder.

Authors:  Bankole A Johnson
Journal:  Alcohol Clin Exp Res       Date:  2017-02-25       Impact factor: 3.455

Review 5.  Development of medications for alcohol use disorders: recent advances and ongoing challenges.

Authors:  Raye Z Litten; Joanne Fertig; Margaret Mattson; Mark Egli
Journal:  Expert Opin Emerg Drugs       Date:  2005-05       Impact factor: 4.191

6.  The Alcohol Clinical Trials Initiative (ACTIVE): purpose and goals for assessing important and salient issues for medications development in alcohol use disorders.

Authors:  Raymond F Anton; Raye Z Litten; Daniel E Falk; Joseph M Palumbo; Raymond T Bartus; Rebecca L Robinson; Henry R Kranzler; Thomas R Kosten; Roger E Meyer; Charles P O'Brien; Karl Mann; Didier Meulien
Journal:  Neuropsychopharmacology       Date:  2011-09-07       Impact factor: 7.853

7.  A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence.

Authors:  Raye Z Litten; Megan L Ryan; Joanne B Fertig; Daniel E Falk; Bankole Johnson; Kelly E Dunn; Alan I Green; Helen M Pettinati; Domenic A Ciraulo; Ofra Sarid-Segal; Kyle Kampman; Mary F Brunette; Eric C Strain; Nassima A Tiouririne; Janet Ransom; Charles Scott; Robert Stout
Journal:  J Addict Med       Date:  2013 Jul-Aug       Impact factor: 3.702

8.  Clinical Validation of Reduced Alcohol Consumption After Treatment for Alcohol Dependence Using the World Health Organization Risk Drinking Levels.

Authors:  Katie Witkiewitz; Kevin A Hallgren; Henry R Kranzler; Karl F Mann; Deborah S Hasin; Daniel E Falk; Raye Z Litten; Stephanie S O'Malley; Raymond F Anton
Journal:  Alcohol Clin Exp Res       Date:  2016-12-26       Impact factor: 3.455
  8 in total
  3 in total

Review 1.  Prevention, screening, and treatment for heavy drinking and alcohol use disorder.

Authors:  Justin Knox; Deborah S Hasin; Farren R R Larson; Henry R Kranzler
Journal:  Lancet Psychiatry       Date:  2019-10-17       Impact factor: 27.083

2.  Reduction in Nonabstinent WHO Drinking Risk Levels and Change in Risk for Liver Disease and Positive AUDIT-C Scores: Prospective 3-Year Follow-Up Results in the U.S. General Population.

Authors:  Justin Knox; Melanie Wall; Katie Witkiewitz; Henry R Kranzler; Daniel Falk; Raye Litten; Karl Mann; Stephanie S O'Malley; Jennifer Scodes; Raymond Anton; Deborah S Hasin
Journal:  Alcohol Clin Exp Res       Date:  2018-10-03       Impact factor: 3.455

Review 3.  Overcoming the "Valley of Death" in Medications Development for Alcohol Use Disorder.

Authors:  Lara A Ray; Spencer Bujarski; Daniel James Olan Roche; Molly Magill
Journal:  Alcohol Clin Exp Res       Date:  2018-07-30       Impact factor: 3.455
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.